Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomized phase II trial. Eligible subjects will be randomized in a
1:1 ratio and stratified for known prognostics variables to one of two first-line medication
treatment arms. Once disease progression has been documented, and following a required
inter-line washout period, subjects will receive either second-line medication treatment or
discontinue treatment, per discretion of treating investigator.